Skip to main content
SpringerLink
Log in

AEs associated with disease-modifying therapies in RRMS

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Sladowska K, et al. Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis Neurological Sciences : 21 Jun 2022. Available from: URL: https://doi.org/10.1007/s10072-022-06197-3

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

AEs associated with disease-modifying therapies in RRMS. Reactions Weekly 1912, 9 (2022). https://doi.org/10.1007/s40278-022-17712-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-17712-3

Search

Navigation